

Limitations of muscle biopsy in Pompe disease

John Vissing

From Proceedings of the 6th European Symposium: Steps Forward in Pompe Disease Berlin, Germany. 23-24 November 2012

The diagnosis of Pompe disease in children and adults can be challenging because of the heterogeneous clinical presentation and considerable overlap of signs and symptoms found in other neuromuscular diseases. This review evaluates the use of muscle biopsy and other methods for the diagnosis and differential diagnosis of late-onset Pompe disease. Muscle biopsy is commonly used as an early diagnostic tool in the evaluation of muscle disease. However, experience has shown that relying solely on visualizing a Periodic acid-Schiff-positive vacuolar myopathy to identify late-onset Pompe disease often leads to false-negative results, and subsequently delays diagnosis and treatment of the disorder. Serum creatine kinase can be normal or only mildly elevated in late-onset Pompe, so is also not very helpful alone to suggest the diagnosis, but may, in combination with proximal and axial weakness, raise the suspicion for Pompe disease. The optimal initial test for confirming or excluding Pompe disease is a simple, bloodbased assay to measure the level of α -glucosidase activity. In particular, measurement of GAA activity in dried blood specimens is minimally invasive, quick, cost-effective, and reliable. Blood-based assays allow for the timely and accurate diagnosis of late-onset Pompe disease, and are likely to improve patient outcomes, as care standards, including enzyme replacement therapy, can be applied and complications may be anticipated and avoided. Increased awareness of the clinical phenotype of Pompe disease is essential in order to expedite diagnostic screening using blood-based, enzymatic assays.

Published: 29 May 2013

doi:10.1186/1471-2474-14-S2-O5 Cite this article as: Vissing: Limitations of muscle biopsy in Pompe disease. *BMC Musculoskeletal Disorders* 2013 14(Suppl 2):O5.

Neuromuscular Research Unit, Department of Neurology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark



Open Access

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

BioMed Central

Submit your manuscript at www.biomedcentral.com/submit



© 2013 Vissing; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.